Skip to main content

Search

Janssen Vaccine Technology

Janssen Vaccine Technology

Our advanced technologies are the driving force behind our strong line of research and vaccine development. By using these technologies, we can better prepare for life-threatening outbreaks of infectious diseases. In this way, we do our part to combat infectious diseases and help people around the world.

Our innovative vaccine technology platform - AdVac®

 

Our innovative vaccine technology platform - AdVac® - offers hope for accelerated vaccine development. We have been using this technology for years to help prevent and combat life-threatening outbreaks of infectious diseases around the world.

The AdVac® technology has already been applied in the development and production of our Ebola vaccine, which is currently being deployed in the Democratic Republic of Congo (DRC) and Rwanda. In addition, this technology is being used for the development of candidate vaccines for Zika, RSV and HIV.

During the current COVID-19 outbreak, Janssen's AdVac® technology is being applied in the SARS-CoV-2 vaccine research program.

AdVac® Viral vector technology

 

Janssen's AdVac® vectors are based on a specific type of adenovirus. This type of adenovirus has been genetically modified so that it can no longer multiply in humans and cannot cause disease.

Adenoviruses are a group of viruses that cause the common cold. Because of this they are relatively harmless, and these viruses can be well used to induce desired immune responses in the human body.

AdVac® technology works as follows: an adenovirus is used as a vector (a carrier) of the genetic code of an antigen. Antigens are substances foreign to the human body that trigger an immune response. In our vaccine produced with the AdVac® technology, we use harmless parts of a virus as antigens. These antigens ensure that the immune response to the virus is mimicked without causing a serious reaction.

 

 

 

When the human body experiences the presence of an antigen, it will induce both a prolonged humoral and cellular immune response against the antigen. Humoral immunity is built up by the production of antibodies, cellular immunity is a result of the proliferation of immune cells.

 

 

 

In the future, when the real pathogen enters the body, the body will be able to react to it faster and more effectively. The immune system has a kind of memory and can therefore quickly produce the necessary immune cells and antibodies. This prevents the pathogen from causing a disease.

 

 

 

Our vaccine technology in action

 

At Janssen, we are committed to fighting infectious diseases. We combine research and innovation and strive to prevent, or treat and cure infectious diseases.

Our AdVac® technology is also used in the development of a vaccine against COVID-19. On 30 March 2020, Johnson & Johnson announced the development of a candidate vaccine for COVID-19.

Janssen also reacted during the Ebola virus epidemic in West Africa by accelerating and scaling up the development of the Ebola virus vaccine. This resulted in the production of more than two million vaccine treatments in less than a year. These vaccine treatments are monovalent, which means that they are specific to one pathogen: the Ebola virus.

Janssen in Belgium

 

Read more about our activities in the field of Infectious Diseases and Vaccines and about our other areas of expertise. You can also learn more about Janssen's activities in België and what working at Janssen looks like. Follow us via social media on Twitter, Facebook and LinkedIn to stay up to date on current developments. 

 

 

 

EM-36492 - 25-jun-2020